Narcolepsy and familial advanced sleep-phase syndrome: molecular genetics of sleep disorders

Current Opinion in Genetics and Development

Volumn 17, Issue 3, 2007, Pages 222-227

  Tafti, Mehdi ^a   Dauvilliers, Yves ^b   Overeem, Sebastiaan ^c,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OREXIN;

CIRCADIAN RHYTHM; GENE EXPRESSION; GENETIC POLYMORPHISM; MOLECULAR GENETICS; NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NARCOLEPSY; SLEEP DISORDERS, CIRCADIAN RHYTHM;

ANIMALIA;

EID: 34249701848     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2007.04.007     Document Type: Review

References (34)

1. Dauvilliers Y., Maret S., and Tafti M. Genetics of normal and pathological sleep in humans. Sleep Med Rev 9 (2005) 91-100
2. Overeem S., Mignot E., van Dijk J.G., and Lammers G.J. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18 (2001) 78-105
3. Nishino S., and Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52 (1997) 27-78
4. Jones C.R., Campbell S.S., Zone S.E., Cooper F., DeSano A., Murphy P.J., Jones B., Czajkowski L., and Ptacek L.J. Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans. Nat Med 5 (1999) 1062-1065
5. Dauvilliers Y., Montplaisir J., Molinari N., Carlander B., Ondze B., Besset A., and Billiard M. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 57 (2001) 2029-2033
6. Dauvilliers Y., Maret S., Bassetti C., Carlander B., Billiard M., Touchon J., and Tafti M. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 62 (2004) 2137-2138
7. Juji T., Satake M., Honda Y., and Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24 (1984) 316-319
8. Mignot E., Lin L., Rogers W., Honda Y., Qiu X., Lin X., Okun M., Hohjoh H., Miki T., Hsu S., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68 (2001) 686-699
9. Lecendreux M., Maret S., Bassetti C., Mouren M.C., and Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 12 (2003) 347-348
10. Dauvilliers Y., Carlander B., Rivier F., Touchon J., and Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56 (2004) 905-908
11. Nishino S., Ripley B., Overeem S., Lammers G.J., and Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000) 39-40
12. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong J., Nishino S., and Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
13. Chemelli R.M., Willie J.T., Sinton C.M., Elmguist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
14. Hara J., Beuckmann C.T., Nambu T., Willie J.T., Chemelli R.M., Sinton C.M., Sugiyama F., Yagami K., Goto K., Yanagisawa M., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30 (2001) 345-354
15. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nersimalova S., Aldrich M., Reynolds D., Albin R., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000) 991-997
16. Olafsdottir B.R., Rye D.B., Scammell T.E., Matheson J.K., Stefansson K., and Gulcher J.R. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 57 (2001) 1896-1899
17. Hungs M., Lin L., Okun M., and Mignot E. Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 57 (2001) 1893-1895
18. Hohjoh H., Nakayama T., Ohashi J., Miyagawa T., Tanaka H., Akaza T., Honda Y., Juji T., and Tokunaga K. Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens 54 (1999) 138-145
19. Wieczorek S., Gencik M., Rujescu D., Tonn P., Giegling I., Epplen J.T., and Dahmen N. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 61 (2003) 437-442
20. Kato T., Honda M., Kuwata S., Juji T., Kunugi H., Nanko S., Fukuda M., and Honda Y. Novel polymorphism in the promoter region of the tumor necrosis factor alpha gene: No association with narcolepsy. Am J Med Genet 88 (1999) 301-304
21. Rubio J.P., Bahlo M., Stankovich J., Burfoot R.K., Johnson L.J., Huxtable S., Butzkuerven H., Lin L., Taylor B.V., Speed T.B., et al. Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. Immunogenetics 59 (2007) 177-186. Extended HLA haplotype analysis in multiple sclerosis and narcolepsy, revealing that the susceptibility haplotype is limited to a class II region and includes TNFA in narcolepsy only.
22. Wieczorek S., Jagiello P., Arning L., Dahmen N., and Epplen J.T. Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA. J Mol Med 82 (2004) 696-705
23. Nakayama J., Miura M., Honda M., Miki T., Honda Y., and Arinami T. Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 65 (2000) 84-86
24. Dauvilliers Y., Blouin J.L., Neidhart E., Carlander B., Eliaou J.F., Antonarakis S.E., Billiard M., and Tafti M. A narcolepsy susceptibility locus maps to a 5 Mb region of chromosome 21q. Ann Neurol 56 (2004) 382-388. The first localization of a familial narcolepsy susceptibility locus.
25. Kawashima M., Tamiya G., Oka A., Hohjoh H., Juji T., Ebisawa T., Honda Y., Inoko H., and Tokunaga K. Genomewide association analysis of human narcolepsy and a new resistance gene. Am J Hum Genet 79 (2006) 252-263. Localization of a protective gene against narcolepsy in Japanese.
26. Panda S., Hogenesch J.B., and Kay S.A. Circadian rhythms from flies to human. Nature 417 (2002) 329-335
27. Reppert S.M., and Weaver D.R. Coordination of circadian timing in mammals. Nature 418 (2002) 935-941
28. Lowrey P.L., and Takahashi J.S. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 5 (2004) 407-441
29. Toh K.L., Jones C.R., He Y., Eide E.J., Hinz W.A., Virshup D.M., Ptacek L.J., and Fu Y.H. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 291 (2001) 1040-1043
30. Zheng B., Larkin D.W., Albrecht U., Sun Z.S., Sage M., Eichele G., Lee C.C., and Bradley A. The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature 400 (1999) 169-173
31. Xu Y., Padiath Q.S., Shapiro R.E., Jones C.R., Wu S.C., Saigoh N., Saigoh K., Ptacek L.J., and Fu Y.H. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature 434 (2005) 640-644. Detailed study of the functional effects of a CK1δ, both in vitro and in transgenic mice.
32. Xu Y., Toh K.L., Jones C.R., Shin J.Y., Fu Y.H., and Ptacek L.J. Modeling of a human circadian mutation yields insights into clock regulation by PER2. Cell 128 (2007) 59-70. Report on a humanized mouse model to understand the role of hPER2 mutation in clock regulation.
33. Vanselow K., Vanselow J.T., Westermark P.O., Reischl S., Maier B., Korte T., Herrmann A., Herzel H., Schlosser A., and Kramer A. Differential effects of PER2 phosphorylation: molecular basis for the human familial advanced sleep phase syndrome (FASPS). Genes Dev 20 (2006) 2660-2672. Extensive in vitro study showing differential effects of PER2 phosphorylation at different sites.
34. Gallego M., Eide E.J., Woolf M.F., Virshup D.M., and Forger D.B. An opposite role for tau in circadian rhythms revealed by mathematical modeling. Proc Natl Acad Sci USA 103 (2006) 10618-10623. Mathematical models of the effects of CK1 mutation explain the various experimental data previously obtained.